If you have been reading about GIP receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Lindow Man, also known as Lindow II and (in jest) as Pete Marsh, is the preserved bog body of a man discovered in a peat bog at Lindow Moss near Wilmslow in Cheshire, North West England. The remains were found on 1 August 1984 by commercial peat cutters. Lindow Man is not the only bog body to have been found in the moss; Lindow Woman was discovered the year before, and other body parts have also been recovered. The find was described as "one of the most significant archaeological discoveries of the 1980s" and caused a media sensation. It helped invigorate the study of British bog bodies, which had previously been neglected. Dating the body has proven problematic, but it is thought that he was deposited into Lindow Moss, face down, sometime between 2 BC and 119 AD, in either the Iron Age or Romano-British period. At the time of death, Lindow Man was a healthy male in his mid-20s, and may have been of high social status as his body shows little evidence of having done heavy or rough physical labour during his lifetime. There has been debate over the reason for his death; his death was violent and perhaps ritualistic. The recovered body has been preserved by freeze-drying and is on permanent display at the British Museum, although it occasionally travels to other venues such as the Manchester Museum.
His season high for strikeouts that year was just seven, achieved in a complete game, four-hit, 4–1 victory over Chicago on September 10. In 30 games (29 starts), he had a 10–14 record, 80 strikeouts, and 91 walks in 189+2⁄3 innings pitched. His 14 losses tied with Bob Friend, Roberts, and Curt Simmons for third in the league (behind Kline's 16 and Johnny Podres's 15), but his 3.42 ERA ranked eighth. Sports Illustrated reported, "Mizell and [Larry] Jackson had impressive ERAs between them but lost more than they won." After working out at the YMCA across from Busch Stadium during the 1958–59 offseason, Mizell showed a stronger fastball in 1959. He did not pitch at the beginning of spring training as he negotiated for a new contract, but he wound up settling for $17,000, his salary each of the previous two seasons. On May 15, he had a season-high 10 strikeouts, allowing just four hits and two unearned runs in an 8–2 victory over the Phillies. He had eight strikeouts in the second game of a doubleheader against Philadelphia on June 7, limiting the Phillies to five hits in a 2–0 shutout victory. In the first half of the season, he enjoyed a 9–3 record and a 3.05 ERA. He was named to both National League All-Star teams in 1959 (in those days, two All-Star games were played in a season). However, he did not appear in either game. The second half of the season saw him post a 4–7 record and a 5.94 ERA. On July 19, 1959, Mizell allowed three runs over seven innings to defeat the Braves, 9–5.
==== Addiction ==== Arguably, some people pursue ineffective shortcuts to feeling good. These shortcuts create positive feelings, but are problematic, in part because of the lack of effort involved. Some examples of these shortcuts include shopping, drugs, chocolate, loveless sex, and TV. These are problematic pursuits because all of these examples have the ability to become addictive. When happiness comes to us so easily, it comes with a price we may not realize. This price comes when taking these shortcuts is the only way to become happy, otherwise viewed as an addiction. A review by Amy Krentzman on the Application of Positive Psychology to Substance Use, Addiction, and Recovery Research, identified, in the field of positive psychology, three domains that allow an individual to thrive and contribute to society. One of these, A Pleasant Life, involves good feelings about the past, present, and future. To tie this with addiction, they chose an example of alcoholism. Research on positive affect and alcohol showed a majority of the population associates drinking with pleasure. The pleasure one feels from alcohol is known as somatic pleasure, which is immediate but a short lived sensory delight. The researchers wanted to make clear pleasure alone does not amount to a life well lived; there is more to life than pleasure. Secondly, the Engaged Life is associated with positive traits such as strength of character.
=== Reproduction === Many marine organisms use pheromones as chemical cues alerting possible mates that they are ready to reproduce. For example, male sea lampreys attract ovulating females by emitting a bile that can be detected many meters downstream. Other processes can be more complex, such as the mating habits of crabs. Due to the fact that female crabs can only mate during a short period after moults from her shell, female crabs produces pheromones before she begins to moult in order to attract a mate. Male crabs will detect these pheromones and defend their potential mate until she has finished molted. However, due to the cannibalistic tendencies of crabs, the female produces an additional pheromone to suppresses cannibalistic instincts in her male guardian. These pheromones are very potent—so much so that they can induce male crabs to try to copulate with rocks or sponges that have been coated in pheromone by researchers. Furthermore, compound structure plays a key role, e.g. crab pheromones are specialized to travel in aquatic vs terrestrial environments.
Sources: en.wikipedia.org
On 12 March, Pakistani officials stated that their military forces targeted and destroyed several Taliban border outposts along the border. Pakistani officials also released images of their attacks which appeared to show multiple posts being hit by air strikes. However, Taliban officials said that Pakistani forces shelled parts of Khost and Kunar provinces, killing four civilians and injuring three others. Taliban claimed to have conducted drone strikes on a Pakistani fort and a command center in Kohat, claiming to have inflicted casualties. On 13 March, the PAF launched multiple airstrikes targeting areas in Kabul, Kandahar, Paktia, and Paktika. Taliban spokesman said that Pakistan's airstrike caused civilian casualties and destroyed a fuel depot of the Kam Air airline. Pakistani officials denied Taliban's spokesman allegations and stated that PAF targeted Taliban military sites and infrastructure in the provinces of Kabul, Kandahar and Paktia. They said the strikes hit facilities linked to 313 Corps and an ammunition depot in Kabul, the Tarawo training center and logistical infrastructure, including a fuel depot, in Kandahar, and the Sher-e-Nau militant camp in Paktia. Pakistani officials also stated that since the start of conflict, at least 663 Afghan Taliban operatives had been killed and more than 887 injured. According to them, Pakistani forces had destroyed 249 check posts, captured 44 more, destroyed 224 tanks, armored vehicles and artillery guns, and carried out air strikes on 70 locations across Afghanistan.
== History == The approach was promulgated as an alternative medicine concept by Andrew Taylor Still, inventor of osteopathy, and his early students. The exact phrase "myofascial release" was coined in the 1960s by Robert Ward, an osteopath who studied with Ida Rolf, the originator of Rolfing. Ward, along with physical therapist John Barnes, are considered the two primary founders of Myofascial Release. Ward also suggests, in other sources, that the term "myofascial release" was coined in 1981, when it was used as the name of a course taught at Michigan State University. It was popularized and taught to therapists, massage therapists and occupational therapists by John F. Barnes through his seminars.
IPT combined with pharmacotherapy was more effective in preventing relapse than pharmacotherapy alone, number needed to treat = 7.63. Couples therapy is sometimes recommended for people with depression. The goal of this therapy is to support the person with depression and emphasize the mutually supportive angle often associated with intimate partners and relationships, and provide mutual support for both partners and help manage any interpersonal changes in their relationship. Psychoanalysis, a school of thought founded by Sigmund Freud that emphasizes the resolution of unconscious mental conflicts, is used by its practitioners to treat clients presenting with major depression. A more widely practiced technique, called psychodynamic psychotherapy, is loosely based on psychoanalysis and has an additional social and interpersonal focus. In a meta-analysis of three controlled trials, psychodynamic psychotherapy was found to be as effective as medication for mild to moderate depression.
Sources: en.wikipedia.org
=== Audio and video === Audio of Ian Smith's radio address announcing UDI 2 years of independence, 1967 Rhodesian MoI film (7 mins) on YouTube Rhodesia to Zimbabwe, collection of film clips (6 mins) on YouTube Songs of UDI, 3 songs from 1977 (9 mins) on YouTube
==== MeSH D12.776.664.235.400 – high mobility group proteins ==== MeSH D12.776.664.235.400.400 – hmgn proteins MeSH D12.776.664.235.400.400.200 – hmgn1 protein MeSH D12.776.664.235.400.400.300 – hmgn2 protein MeSH D12.776.664.235.400.500 – hmga proteins MeSH D12.776.664.235.400.500.100 – hmga1a protein MeSH D12.776.664.235.400.500.200 – hmga1b protein MeSH D12.776.664.235.400.500.300 – hmga1c protein MeSH D12.776.664.235.400.500.600 – hmga2 protein MeSH D12.776.664.235.400.600 – hmgb proteins MeSH D12.776.664.235.400.600.300 – hmgb1 protein MeSH D12.776.664.235.400.600.600 – hmgb2 protein MeSH D12.776.664.235.400.600.800 – hmgb3 protein MeSH D12.776.664.235.400.700 – sex-determining region y protein MeSH D12.776.664.235.400.800 – tcf transcription factors MeSH D12.776.664.235.400.800.500 – lymphoid enhancer-binding factor 1 MeSH D12.776.664.235.400.800.750 – t cell transcription factor 1
Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is sold under the brand names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co., and licensed to Vivus Inc., which partnered with Menarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand. Metuchen Pharmaceuticals obtained exclusive rights within the United States. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum penis. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes. About two-thirds of the participants were able to engage in sexual activity within fifteen minutes.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.